Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
- Journal:
- Journal of Clinical Oncology
- Published:
- DOI:
- 10.1200/jco-24-02463
- Affiliations:
- 18
- Authors:
- 18
| Institutions | Authors | Share |
|---|---|---|
| Kindai University, Japan | 0.14 | |
| Aichi Cancer Center Hospital, Japan | 0.11 | |
| Osaka International Cancer Institute, Japan | 0.06 | |
| Kindai University Hospital, Japan | 0.06 | |
| Hyogo Cancer Center, Japan | 0.06 | |
| Saitama Cancer Center, Japan | 0.06 | |
| National Cancer Center Hospital, Japan | 0.06 | |
| Keio University, Japan | 0.06 | |
| Kanagawa Cancer Center, Japan | 0.06 | |
| Shikoku Cancer Center, Japan | 0.06 | |
| Hokkaido University Hospital, Japan | 0.06 | |
| Kyushu Cancer Center, Japan | 0.06 | |
| The University of Tokyo (UTokyo), Japan | 0.06 | |
| Kyorin University, Japan | 0.06 | |
| Gifu University Hospital, Japan | 0.03 | |
| Gifu University, Japan | 0.03 | |
| Tohoku University, Japan | 0.03 |